Tokyo, Aug. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062309) titled 'Real-world clinical outcomes of adjuvant pembrolizumab following surgery for high-risk renal cell carcinoma: a multicenter retrospective study (SHINSHU study)' on Aug. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu university
Condition:
Condition - renal cell carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the natural course of renal cell carcinoma after surgery
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - Renal cell carcinoma patients who ...